Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)

- The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects

- The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Arch Biopartners Inc

Atox Bio Ltd

Balmes Transplantation SAS

Cellmid Ltd

CFM Pharma ...

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Arch Biopartners Inc

Atox Bio Ltd

Balmes Transplantation SAS

Cellmid Ltd

CFM Pharma Holding BV

Cypralis Ltd

DURECT Corp

Evotec AG

Exponential Biotherapies Inc

F. Hoffmann-La Roche Ltd

GeneScience Pharmaceuticals Co Ltd

Klotho Therapeutics Inc

Kringle Pharma Inc

Mitobridge Inc

Mitotech SA

Quark Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Silver Creek Pharmaceuticals Inc

Spherium Biomed SL

STATegics Inc

Torrent Pharmaceuticals Ltd

Xigen SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview

Acute Renal ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Arch Biopartners Inc

Atox Bio Ltd

Balmes Transplantation SAS

Cellmid Ltd

CFM Pharma Holding BV

Cypralis Ltd

DURECT Corp

Evotec AG

Exponential Biotherapies Inc

F. Hoffmann-La Roche Ltd

GeneScience Pharmaceuticals Co Ltd

Klotho Therapeutics Inc

Kringle Pharma Inc

Mitobridge Inc

Mitotech SA

Quark Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Silver Creek Pharmaceuticals Inc

Spherium Biomed SL

STATegics Inc

Torrent Pharmaceuticals Ltd

Xigen SA

Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles

(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-4102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-0302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-0303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-0401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-4066 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerium oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilastatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Kidney Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DUR-928 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EA-230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IL-233 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iron sucrose + Sn protoporphyrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-1052 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MA-0204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metablok - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTB-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Plastomitin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-190 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Alkaline Phosphatase Enzyme Replacement for Acute Kidney Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Klotho Replacement for Kidney Disease, Aging, Breast Cancer, Cognitive Impairment and Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides to Agonize renalase for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize GHR for Growth Failure In Children With Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reltecimod sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RLS-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RMC-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGF-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PADI4 for Acute Kidney Injury, Hepatic and Pancreatic Injuries - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GGT for Acute Renal Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases, Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STSE-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUL-138 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRC-160334 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vanadis-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects

Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products

Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones

Featured News & Press Releases

Jul 09, 2018: Quark Pharmaceuticals Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

May 29, 2018: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)

May 22, 2018: Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok

May 08, 2018: Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients

Mar 21, 2018: Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury

Mar 09, 2018: AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury

Feb 27, 2018: Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio

Nov 14, 2017: A1M Pharma reports positive results from its GLP toxicology study - now able to finalize application to initiate clinical studies

Nov 07, 2017: Quark Pharmaceuticals to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference

Nov 07, 2017: ROSgard protects bone marrow during radiation treatment - patent application has been filed

Nov 06, 2017: Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPARd Modulators in Acute Kidney Injury at American Society of Nephrology Annual Meeting

Nov 04, 2017: Quark Pharmaceuticals Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting

Nov 01, 2017: Quark Pharmaceuticals Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting

Oct 27, 2017: A1M Pharma: First company in the world with large scale manufacturing of A1M under full GMP compliance for clinical studies

Sep 13, 2017: Patented the first drug that acts as a protector of the kidney

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2018

Number of Products under Development by Companies ...

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Arch Biopartners Inc, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Balmes Transplantation SAS, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by CFM Pharma Holding BV, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cypralis Ltd, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Klotho Therapeutics Inc, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitobridge Inc, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Silver Creek Pharmaceuticals Inc, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2018 (Contd..1), H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2018

Number of Products under Development by Companies ...

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports